Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone vs PLD in Refractory/Resistant Ovarian Cancer
NCT00262990Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Feb 2010
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of patupilone in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Novartis. Primary endpoint: Overall Survival. Started Nov 2005; status: completed.
02
Drugs
patupilone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00262990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262990.